News >

Lurbinectedin Combo Induces Clinical Activity in Chemo-Sensitive SCLC

Kristie L. Kahl
Published: Wednesday, Sep 26, 2018

Martin David Forster, MD, PhD

Martin David Forster, MD, PhD

Lurbinectedin (Zepsyre; PM1183) plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer (SCLC), especially when excluding refractory patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication